Renalytix Announces Fundraise to Bolster Kidney Disease Diagnostics

Renalytix plc (LON: RENX), a precision medicine company specializing in kidney disease diagnostics, has announced its intention to raise a minimum of £4.0 million through a placing, subscription, and retail offer.

The funds will support the continued commercialization and development of kidneyintelX.dkd, its FDA-approved prognostic test.

The company is issuing new ordinary shares at a price of 9.5 pence per share. This represents an 11.6% discount to the closing middle market price on September 19, 2025, but a 39% premium to the 90-day closing average share price. The placing will be conducted via an accelerated bookbuild, led by Oberon Capital.

WELCOME BONUS - Free Share Bundle When You Invest £50! Open a UK Investment Account: Shares, ISAs, Managed Portfolio Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply. IG

5.0

View Offers

Empfohlener Broker Multi Asset Platform

Social-Trading-Pionier mit Aktien, ETFs, Krypto und CFDs, Copy Trading inklusive. eToro

5.0

Weitere Informationen 50% of retail investor accounts lose money when trading CFDs with this provider.

Renalytix already has the necessary shareholder approvals to issue the new shares. The company secured these authorities at its annual general meeting in December 2024, demonstrating foresight in anticipating its capital needs.

Company directors intend to participate in the fundraise, committing approximately £270,000 in total. However, the directors’ shares will be subject to a six-month lock-in period, preventing them from immediately selling their newly acquired shares.

The fundraise aims to fuel Renalytix’s growth strategy, particularly the wider adoption of kidneyintelX.dkd. This test is currently the only FDA-approved and Medicare-reimbursed prognostic tool for early-stage risk assessment in chronic kidney disease.